Gellad Ziad F, Lyles Kenneth W
Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA.
Am J Med. 2007 Jun;120(6):475-80. doi: 10.1016/j.amjmed.2006.09.030.
Since the US Food and Drug Administration (FDA) released new guidelines on broadcast direct-to-consumer advertising in 1997, the prevalence of direct-to-consumer advertising of prescription drugs has increased exponentially. The impact on providers, patients, and the health care system is varied and dynamic, and the rapid changes in the last several years have markedly altered the health care landscape. To continue providing optimal medical care, physicians and other health care providers must be able to manage this influence on their practice, and a more thorough understanding of this phenomenon is an integral step toward this goal. This review will summarize the history of direct-to-consumer drug advertisements and the current regulations governing them. It will summarize the evidence concerning the impact of direct-to-consumer advertising on the public, providers, and the health care system, and conclude with observations regarding the future of direct-to-consumer advertising.
自1997年美国食品药品监督管理局(FDA)发布关于面向消费者的处方药广播广告的新指南以来,面向消费者的处方药广告的普及率呈指数级增长。对医疗服务提供者、患者和医疗保健系统的影响是多样且动态的,过去几年的快速变化显著改变了医疗保健格局。为了继续提供最佳医疗服务,医生和其他医疗保健提供者必须能够应对这种对其医疗实践的影响,而更深入地了解这一现象是朝着这一目标迈出的不可或缺的一步。本综述将总结面向消费者的药品广告的历史以及现行的相关法规。它将总结有关面向消费者的广告对公众、医疗服务提供者和医疗保健系统影响的证据,并对面向消费者的广告的未来发表看法。